Corcept Therapeutics Quarterly Balance Sheet
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corcept Therapeutics financial position
As of Jun 30, 2026, Corcept Therapeutics reported total assets of $888.7 million, up 10.8% from a year earlier against total liabilities of $182.9 million. Shareholders' equity stood at $705.8 million, or 79.4% of assets. The company held $111.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.86, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Corcept Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 111.04M | 108.74M | 120.50M | 125.14M | 102.75M | 89.82M | 127.67M | 137.29M | 128.59M | 149.75M | 135.55M | 111.80M |
| Short-Term Investments | 197.16M | 229.45M | 251.66M | 296.55M | 239.48M | 232.94M | 255.67M | 243.05M | 344.57M | 261.01M | 232.67M | 243.43M |
| Receivables | 76.92M | 39.07M | 59.79M | 69.63M | 64.57M | 61.82M | 53.98M | 59.72M | 53.84M | 61.52M | 41.12M | 34.63M |
| Inventory | 13.19M | 12.89M | 12.87M | 12.35M | 12.28M | 14.37M | 12.41M | 8.05M | 8.35M | 7.19M | 7.73M | 7.51M |
| Total Current Assets | 439.68M | 426.03M | 485.46M | 541.13M | 443.11M | 438.50M | 471.60M | 466.98M | 560.85M | 503.37M | 458.64M | 431.53M |
| Property, Plant & Equipment | 5.13M | 3.17M | 1.89M | 2.09M | 2.35M | 2.54M | 2.69M | 2.93M | 1.47M | 127.00K | 195.00K | 302.00K |
| Long-Term Investments | 236.45M | 177.26M | 160.27M | 102.56M | 172.78M | 248.04M | 219.83M | 167.31M | 19.32M | 40.28M | 57.18M | 59.62M |
| Total Assets | 888.70M | 814.88M | 836.65M | 823.61M | 801.72M | 846.46M | 840.55M | 784.26M | 714.55M | 655.93M | 621.52M | 594.02M |
| Accounts Payable | 14.91M | 33.31M | 40.44M | 34.45M | 23.52M | 27.95M | 15.38M | 18.58M | 19.48M | 12.56M | 17.40M | 16.71M |
| Total Current Liabilities | 153.80M | 149.19M | 166.09M | 172.26M | 144.66M | 143.07M | 140.77M | 126.22M | 100.75M | 97.20M | 104.50M | 121.87M |
| Total Liabilities | 182.93M | 176.89M | 188.85M | 191.71M | 165.93M | 163.17M | 160.96M | 145.42M | 118.31M | 108.07M | 114.81M | 132.34M |
| Shareholders' Equity | 705.78M | 637.99M | 647.80M | 631.90M | 635.79M | 683.28M | 679.59M | 638.84M | 596.24M | 547.86M | 506.70M | 461.68M |
| Retained Earnings | 654.61M | 611.63M | 643.39M | 619.10M | 599.43M | 564.28M | 543.74M | 512.99M | 465.78M | 430.29M | 402.53M | 371.17M |
| Net Cash (Debt) | 308.20M | 338.18M | 372.15M | 421.68M | 342.23M | 322.76M | 383.33M | 380.34M | 473.16M | 410.76M | 368.22M | 355.23M |
| Shares Outstanding | — | — | 105.97M | — | — | — | 105.11M | — | — | — | 103.41M | — |
This table shows 12 quarterly periods of Corcept Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CORT's reporting calendar. What is a balance sheet?